Why this ASX 200 'stable stock' is poised to outperform: Goldman Sachs

According to analysts at Goldman Sachs, stocks with stable earnings growth and share prices have historically tended to outperform when the economy is slowing.

| More on:
A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare share ResMed Inc (ASX: RMD) counts among a select basket of stable stocks that Goldman Sachs believes is set to widely outperform the benchmark.

The company is listed on multiple international exchanges. It focuses on treating a range of sleeping disorders and has seen some sizeable swings its share price over the past year, leaving it right about where it was 12 months ago.

But the ASX 200 medical stock could enjoy a far stronger year ahead.

14% potential share price upside for ResMed

According to analysts at Goldman Sachs, stocks with stable earnings growth and share prices have historically tended to outperform when the economy is slowing. But we've yet to see that with Goldman's basket of stable stocks, which includes ResMed.

"Our economists see greater downside risks than upside risks, suggesting ample opportunities for stable stocks to outperform," the analysts said (courtesy of The Australian Financial Review.)

The broker said that despite the economic slowdown hitting developed nations, stables stocks — like ASX 200 listed ResMed — are trading at "undemanding valuations".

There are no guarantees in the world of investing. But Goldman sees a positive risk-reward trade-off with ResMed shares.

The main risk to owning stable stocks is if economic growth proves to be more resilient than we expect," the broker said. "But low valuations, poor recent performance, and elevated recession risk mean the risk/reward is asymmetric."

In its recent report profiling a range of ASX 200 healthcare stocks, Goldman noted:

We continue to express a general preference for the device/drug names over the service providers in the current environment, on the basis of: i) stronger pricing power; ii) more assured volume profiles; iii) more resilient/expanding market shares; and iv) stronger balance sheets.

As for ResMed specifically, the analysts said, "As operational pressures continue to ease we see margin/cost dynamics improving, both near and long-term."

Goldman is expecting "a sequentially stronger 2H23" for the ASX 200 medical device stock. The analysts forecast an earnings per share compound annual growth rate of 11% over the next three years "with potential upside depending on how competitive dynamics develop".

Sharper-than-expected competitor recovery and potentially new disruptive therapies are the key risks to this outlook.

Goldman has a buy rating on ResMed shares with a target price of $38.00. That's 13.8% above the current share price.

How has this ASX 200 stable stock been tracking?

As you can see in the chart below, the ResMed share price is just about flat over the past 12 months. So far in 2023, the ASX 200 stable stock has gained 7.8%.

Created with Highcharts 11.4.3ResMed PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »